Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 14/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25808148 | 0.83 | SLC29A1 (0.51) | SLC29A1ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL22577618 | 0.82 | SLC29A1 (0.61) | SLC29A1ADORA1ADORA2AADORA2B | |
| SCHEMBL22577548 | 0.80 | TYMP (0.66) | TYMPADORA1 | |
| SCHEMBL20547881 | 0.77 | TYMP (0.69) | TYMPADORA1 | |
| SCHEMBL22577537 | 0.75 | TYMP (0.60) | TYMPADORA1 | |
| SCHEMBL21586639 | 0.75 | TYMP (0.66) | TYMPADORA1 | |
| SCHEMBL23630131 | 0.74 | TYMP (0.72) | TYMPSLC29A1ADORA1 | |
| SCHEMBL20579728 | 0.74 | TYMP (0.72) | TYMPSLC29A1ADORA1 | |
| SCHEMBL22458251 | 0.73 | TYMP (0.86) | TYMPSLC29A1ADORA1 | |
| SCHEMBL24201469 | 0.73 | TYMP (0.86) | TYMPSLC29A1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
| EP-3727401-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | TYMP 2186/4885SLC29A1 252/4885ADORA1 34/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | TYMP 2396/4885SLC29A1 231/4885ADORA1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.